(IN BRIEF) Evonik is now offering customers cradle-to-gate Life Cycle Assessment (LCA) data for selected EUDRAGIT® functional polymers, using its TÜV-certified LCA methodology to support pharmaceutical companies with transparent environmental data for Scope 3 emissions reporting. The data is currently … Read the full press release
Posted in Business, Chemicals, Environment, Healthcare, Industrial, Pharma & Biotech, Science, Technology
Tagged 2030 sustainability targets, climate neutrality, coatings, cradle-to-gate assessment, Custom Solutions, Darmstadt, data-driven decisions, delayed release, Dr Jürgen Krauter, drug delivery, emissions reporting, energy use, environmental footprint, environmental transparency, ESG requirements, Essen, EUDRAGIT, EUDRAGIT L 100-55, EUDRAGIT L 30 D-55, EUDRAGIT® L 100-55 Shows 6 Percent Product Carbon Footprint Reduction, Evonik, Evonik Expands Sustainability Transparency for EUDRAGIT® Functional Polymers, Evonik Health Care, Evonik Industries AG, Evonik Offers Cradle-to-Gate LCA Data for Pharmaceutical Excipients, Functional Polymers, Germany, healthcare sustainability, hot melt extrusion, immediate release, Janusz Berger, LCA data, life cycle assessment, Muhammad Irfan, Next Generation Solutions, Oral Drug Delivery Solutions, PCF, pharmaceutical excipients, pharmaceutical processes, pharmaceutical products, pharmaceutical value chain, polymethacrylates, poorly soluble drug substances, process efficiency, product carbon footprint, renewable electricity, Scope 1 emissions, scope 2 emissions, Scope 3 emissions, solubility enhancement, spray drying, spray drying system, surface treatments, sustainability strategy, sustained release, Thilo Krapfl, TRANSPORT, TÜV-certified LCA methodology
(IN BRIEF) dsm-firmenich has announced that Thomas Leysen, Chair of the Board of Directors, has decided to retire from the Board once shareholders elect a successor, following the completion of the company’s merger and the setting of its strategic direction. … Read the full press release
Posted in Apparel, Fashion & Beauty, Business, Chemicals, Financial, Food & Beverage, Germany, Healthcare, Management, Netherlands, Pharma & Biotech, Switzerland
Tagged Animal Nutrition & Health divestment, Article 53 Listing Rules, Board of Directors, board succession, Brenntag SE, Capital Markets Day, Chair of the Board, Chairman of the Board, Cognis, continuing operations, corporate governance, Dave Huizing, dsm-firmenich, dsm-firmenich Board Thanks Thomas Leysen and Proposes Successor, dsm-firmenich Calls EGM to Vote on Richard Ridinger as New Chairman, dsm-firmenich Plans Board Leadership Transition With Richard Ridinger Nomination, EGM, Euronext Amsterdam, Executive Committee, extraordinary general shareholders meeting, Firmenich, flavours, fragrances, Germany, health and beauty, Healthcare, Henkel, Independent Director, Kaiseraugst, leadership transition, life sciences, long-term value creation, Lonza, Maastricht, margin improvement program, merger completion, Natural Ingredients, Netherlands, Nomination and Governance Committee, NOVO Holdings, Nutrition, portfolio tuning, Recipharm AG, renewable ingredients, Richard Ridinger, Robin Roothans, shareholder approval, SIX Swiss Exchange, specialty chemicals, strategic direction, Switzerland, Thomas Leysen, €9 billion revenue
(IN BRIEF) Sandoz has announced a major strategic collaboration with Shanghai Henlius Biotech, Inc. covering up to 10 biosimilar assets, in one of the largest biosimilar collaborations in Sandoz’s history. Under the agreement, Sandoz will receive global commercialisation rights outside … Read the full press release
Posted in Business, Financial, Healthcare, International Trade, Investment, Law, News, Pharma & Biotech, Science, Switzerland
Tagged 02696, 39 assets, affordable medicines, Alexis Kalomparis, Basel, belimumab, Benlysta, biosimilar pipeline, biosimilars, Cardiovascular risk, cetuximab, CHINA, Chris Lewis, clinical development, commercialisation rights, Craig Marks, development agreement, early development, epidermal growth factor receptor, ERBITUX, evolocumab, global affordable medicines, global commercialisation rights outside China, healthcare savings, Henlius, HKEx, hypercholesterolaemia, ImClone LLC, ipilimumab, loss of exclusivity, lupus nephritis, manufacturing agreement, Marina Konrad-Maerk, metastatic colorectal cancer, milestone-based agreement, oncology therapy, OTCQX®, patient access, recombinant human hyaluronidase, Repatha, Richard Saynor, Samsung Bioepis, Sandoz, Sandoz and Henlius Announce Strategic Collaboration Covering Up to 10 Biosimilars, Sandoz Expands Biosimilar Pipeline Through Major Henlius Collaboration, Sandoz Secures Global Rights Outside China for Up to 10 Henlius Biosimilar Assets, SDZ, SDZNY, Shanghai Henlius Biotech, Silvia Siegfried, SIX Swiss Exchange, squamous cell carcinoma of the head and neck, strategic collaboration, subcutaneous administration, Switzerland, systemic lupus erythematosus, Tamara Hackl, Technical Development, up to 46 assets, USD 100.5 million, USD 322 million
(IN BRIEF) A new Novonesis-commissioned report, “The Value of Biosolutions: Growth and Prosperity to 2035 – Japan Edition,” finds that biosolutions could help Japan strengthen its position as a global biomanufacturing hub and support its ambition to realise one of … Read the full press release
Posted in Agriculture, Business, Denmark, Economy, Energy, Gas & Oil, Environment, Food & Beverage, Government, Industrial, News, Pharma & Biotech, Science, Technology
Tagged 2.1 additional jobs, 2.4 global average, 2030 bioeconomy ambition, 2035 growth, ADC, agriculture, Amsterdam Data Collective, Bioeconomy Strategy, bioenergy policy advocacy, biofuel mandates, biofuels, biomanufacturing hub, biosolutions, Biosolutions Could Strengthen Japan’s Biomanufacturing and Bioeconomy Ambitions, biotechnology, commercial-scale manufacturing, Denmark, energy resilience, energy savings, enzymes, fast-track regulatory pathway, financial incentives, food enzyme market access, food production, food security, fossil resources, global bioeconomy, Growth and Prosperity to 2035 Japan Edition, Hirokazu Sano, industrial manufacturing, Industrial Systems, Japan, Japan bioeconomy, Jarl Frijs-Madsen, JPY 4.748 trillion, Lyngby, microbes, Novonesis, Novonesis Japan Ltd., Novonesis-Commissioned Report Calls for Faster Biosolutions Approvals in Japan, policy leadership, preventive health, proteins, public awareness, regulatory approvals, Report Identifies Policy Pathways to Accelerate Japan’s Biosolutions Economy, resource efficiency, Royal Danish Embassy in Japan, social acceptance, Supply Security, sustainable food systems, synthetic biology, Synthetic Biology and Biotechnology Growth Strategy, The Value of Biosolutions, Tokyo, waste reduction, water savings
(IN BRIEF) SCHOTT Pharma has reaffirmed its commitment to science-based climate action after the Science Based Targets initiative (SBTi) validated the updated climate targets of the SCHOTT Group, including SCHOTT Pharma’s business scope. The updated framework keeps the Group’s target … Read the full press release
Posted in Business, Energy, Gas & Oil, Environment, Germany, Healthcare, News, Pharma & Biotech, Science, Switzerland, Technology
Tagged 1.5°C pathway, 2019 baseline, 27.5 percent Scope 3 reduction, 46.2 percent emissions reduction, Alliance to Zero, Carl Zeiss Foundation, circular economy, Climate Action, climate neutral by 2030, decarbonisation, drug delivery systems, Energize, energy attribute certificates, energy efficiency, EUR 986 million revenue, fiscal year 2030, Frankfurt Stock Exchange, Germany, GHG emissions, glass tubing, greenhouse gas emissions, healthcare value chain, heat recovery, injectable drugs, Lea Kaiser, low-emission melting technologies, Mainz, membrane-based system, natural gas reduction, Paris Agreement, pharmaceutical containment solutions, pharmaceutical quality, product carbon footprint, regulatory requirements, Reinhard Mayer, renewable electricity sourcing, renewable energy, SBTi, SCHOTT Group, SCHOTT Pharma, SCHOTT Pharma Reaffirms Science-Based Climate Action Following SBTi Validation, SCHOTT Pharma Shifts Climate Strategy Toward Measurable Scope 3 Emissions Reductions, SCHOTT Pharma Targets Value Chain Emissions With Updated Science-Based Climate Framework, Science Based Targets initiative, science-based targets, Scope 1 emissions, scope 2 emissions, Scope 3 emissions, secondary packaging, supplier decarbonisation, Switzerland, technological innovation, updated climate targets, value chain emissions, water efficiency, Water for Injection, WFI
(IN BRIEF) Swissport has opened a new 630-square-metre temperature-controlled cargo facility at Kilimanjaro International Airport, strengthening its African cargo network and increasing cold chain capacity for East Africa’s growing perishables export market. The facility, already operational, supports storage temperatures from … Read the full press release
Posted in Aviation & Aerospace, Business, Environment, Food & Beverage, Infrastructure & Utilities, International Trade, Investment, Pharma & Biotech, Switzerland, Technology, Transportation & Logistics, Travel
Tagged +2°C to +25°C storage, -10°C to -20°C frozen storage, 000 tons annual capacity, 120 cargo centres, 13, 180 tons cargo capacity, 36 built-up cargo pallets, 630 square metres, Accra, African cargo network, air cargo, air freight logistics, airlines, automated cargo tracking, aviation services, cargo handling, cargo management platform, cargo traceability, Cold Chain Facility, cold storage, dangerous goods, Dar es Salaam, Dirk Goovaerts, e-commerce shipments, East Africa, electric ground support equipment, exporters, express freight, flowers, four chillers, freezer, freight forwarders, fresh produce, global cargo centres, horticultural exports, Integrated Weighing System, international trade lanes, ISO 14001, Johannesburg, Kilimanjaro, Kilimanjaro International Airport, LED lighting, meat, mobile cargo scanning, Nairobi, New Swissport Facility Boosts Cold Chain Capacity for East African Perishables Exports, perishables export market, pharmaceuticals, seafood, shipment visibility, specialist cargo handling, sustainable operations, Swissport, Swissport Opens New Cold Chain Cargo Facility at Kilimanjaro International Airport, Swissport Strengthens Kilimanjaro Cargo Operations With Modern Cold Storage Infrastructure, Tanzania, Tanzania Northern Circuit, temperature-controlled cargo, temperature-sensitive shipments
(IN BRIEF) EQT Life Sciences is investing USD 17.5 million in Vaderis Therapeutics as part of the Swiss biotechnology company’s USD 152 million Series B financing. The funding will support the global Phase 3 HEROIC study of engasertib, Vaderis’ lead … Read the full press release
Posted in Business, Financial, Healthcare, Investment, Pharma & Biotech, Science, Sweden, Switzerland, Technology
Tagged Azmi Nabulsi, biotechnology investment, Christoph Broja, chronic anemia, clinical-stage biotechnology, Droia, engasertib, epistaxis, EQT Life Sciences, EQT Life Sciences Backs Vaderis Therapeutics’ Phase 3 Development of Engasertib, EQT Life Sciences Invests USD 17.5 Million in Vaderis Therapeutics Series B, global Phase 3 trial, Goldman Sachs Alternatives, hereditary hemorrhagic telangiectasia, HEROIC study, HHT, inherited blood vessel disorder, Kalehua Capital, late-stage clinical development, long-term extension data, Medicxi, no approved therapies, Omega Funds, Patient Advocacy, Perceptive Advisors, phase 3 study, pivotal development, proof-of-concept data, rare disease therapy, rare genetic vascular disease, rare vascular disease, regulatory approval, Series B financing, severe nosebleeds, Swiss biotechnology company, targeted therapies, TCGX, The New England Journal of Medicine, USD 152 million financing, USD 17.5 million investment, Vaderis Therapeutics, Vaderis Therapeutics Secures USD 152 Million Series B to Advance HHT Therapy, vascular abnormalities
(IN BRIEF) Almirall is reinforcing its commitment to innovation in medical dermatology, with a focus on science, collaboration and patient needs. The company’s teams work to improve understanding of skin diseases and address complex dermatological challenges through research and multidisciplinary … Read the full press release
Posted in Business, Healthcare, Pharma & Biotech, Science, Spain, Technology
Tagged Almirall, Almirall Combines Science and Patient Insight to Advance Medical Dermatology, Almirall Highlights Purpose-Led Innovation in Dermatology, Almirall Strengthens Scientific Focus on Skin Disease Research, better care, Dermatology, dermatology innovation, dermatology pipeline, disease understanding, Healthcare Innovation, healthier future, innovation through science, long-term ambition, medical dermatology, multidisciplinary teams, patient needs, patient outcomes, patient wellbeing, patient-centred innovation, patients’ lives, purpose-led science, quality of life, research collaboration, researchers, scientific excellence, scientific expertise, scientific research, scientists, skin conditions, skin disease research, skin diseases, skin science, treatment innovation, unmet medical needs
(IN BRIEF) Almirall has entered into a collaboration and licensing agreement with CrystalO for the discovery and development of novel small molecules in medical dermatology. Under the agreement, CrystalO will handle candidate discovery, optimisation, IND-enabling studies and early clinical development, … Read the full press release
Posted in Business, Healthcare, International Trade, Investment, Pharma & Biotech, Science, Spain, Technology
Tagged Almirall, Almirall and CrystalO Enter Licensing Agreement for Dermatology Drug Discovery, Almirall Expands Medical Dermatology Pipeline Through CrystalO Collaboration, Almirall Partners With CrystalO to Develop Novel Small Molecules in Medical Dermatology, candidate discovery, candidate optimisation, clinical proof of concept, collaboration agreement, Commercialisation, CrystalO, Dermatology, dermatology treatments, differentiated treatments, Dr Zhang Jin, drug discovery, early clinical development, exclusive rights outside mainland China, external innovation, Global Development, IND-enabling studies, innovation strategy, innovative medicines, ion channel drug discovery, Karl Ziegelbauer, licensing agreement, local R&D programmes, Mainland China, Manufacturing, medical dermatology, novel small molecules, patient benefits, pharmaceutical research, PoC, R&D Pipeline, scientific collaboration, skin conditions, small molecule discovery, strategic collaboration, technology platform, therapeutic development, unmet medical need
(IN BRIEF) QIAGEN has received U.S. FDA clearance for the QIAstat-Dx BCID GPF Plus AMR Panel, its first QIAstat-Dx bloodstream infection panel cleared for the U.S. market. The panel detects 20 gram-positive bacterial and fungal pathogen targets, a broad pan … Read the full press release
Posted in Business, Germany, Government, Healthcare, Netherlands, Pharma & Biotech, Science, Technology
Tagged 100 countries, 200 placements, 5, AMR, antibiotic use, antimicrobial resistance markers, antimicrobial stewardship, bloodstream infection diagnostics, bloodstream infections, clinical decision making, data analysis, FDA, FDA Clears QIAGEN QIAstat-Dx Panel for Rapid Bloodstream Infection Testing, FDA review, Frankfurt Prime Standard, fungal pathogens, gastrointestinal panel, genetic resistance markers, Germantown, gram-positive bacteria, infection prevention, infectious disease testing, laboratory diagnostics, Maryland, meningitis encephalitis panel, Molecular Diagnostics, multiplex PCR, Netherlands, Nitin Sood, one-hour results, pan gram-negative target, pathogen detection, positive blood cultures, QGEN, QIA, QIAGEN, QIAGEN Launches First FDA-Cleared QIAstat-Dx BCID Panel for U.S. Laboratories, QIAstat-Dx, QIAstat-Dx BCID GN Plus AMR Panel, QIAstat-Dx BCID GPF Plus AMR Panel, QIAstat-Dx BCID GPF Plus AMR Panel Detects Pathogens and Resistance Markers in About One Hour, QIAstat-Dx Gastrointestinal Panel 2, QIAstat-Dx GI Panel 2 Mini B, QIAstat-Dx GI Panel 2 Mini B&V, QIAstat-Dx Meningitis/Encephalitis Panel, QIAstat-Dx Respiratory Panel Mini, QIAstat-Dx Respiratory Panel Plus, rapid testing, respiratory panel, sample preparation, SEPSIS, syndromic testing, U.S. Food and Drug Administration, U.S. laboratories, Venlo
(IN BRIEF) Novonesis has signed an agreement with the intent to acquire MicroBioGen, an Australian biotechnology company specialising in yeast strains for industrial applications, particularly bioethanol. The planned acquisition builds on Novonesis’ 2013 investment in MicroBioGen and its current 23 … Read the full press release
Posted in Business, Chemicals, Denmark, Energy, Gas & Oil, Financial, Food & Beverage, Industrial, Investment, Pharma & Biotech, Science
Tagged 2013 investment, 2030 strategy, 23 percent stake, ACCC, acquisition agreement, Australia, Australian Competition and Consumer Commission, baking applications, bioethanol, biological solutions, biosolutions, biotechnology, biotechnology acquisition, Claus Crone Fuglsang, Copenhagen, customary approvals, decade-long collaboration, Denmark, disciplined investment, elite yeast genetics, energy applications, Ester Baiget, food applications, Geoffrey Bell, industrial applications, industrial fermentation, industrial yeast, Innova yeast series, MicroBioGen, microbiology, Novonesis, Novonesis Expands Yeast Capabilities Through Planned MicroBioGen Acquisition, Novonesis Targets Bioethanol and Fermentation Growth With MicroBioGen Deal, Novonesis to Acquire MicroBioGen to Strengthen Yeast Biotechnology Platform, platform technology, pure-play biology company, R&D capabilities, regulatory approvals, research and development, sustainable feed, transaction terms undisclosed, yeast biotechnology, yeast innovation as a service, yeast strains
(IN BRIEF) Researchers at The Institute of Cancer Research, London, working with Merck KGaA, have developed the first potent small-molecule inhibitors of DHX8, an enzyme involved in pre-mRNA splicing. The compounds are described as “pathfinder molecules” rather than drug candidates, … Read the full press release
Posted in Business, Germany, Healthcare, Investment, Pharma & Biotech, Science, Technology, United Kingdom
Tagged biochemical tests, cancer biology, cancer diversity, Cancer Drug Discovery, cancer evolution, Cancer Research UK, cancer stress responses, cancer-selective therapeutic window, Centre for Cancer Drug Discovery, chemical probes, compound 53, crystal structure, DEAH-box RNA helicases, DHX8, Dr Rob van Montfort, drug resistance, fragment-based drug design, gene expression, hard-to-drug targets, helicase domain, Hit Discovery and Structural Design Group, HSF1, ICR, ICR and Merck KGaA Advance Fragment-Based Approach to Target DHX8, Journal of Medicinal Chemistry, lung cancer cells, Medicinal Chemistry, Merck KGaA, mRNA splicing, nanomolar concentrations, New Small-Molecule Inhibitors Open Route to Underexplored RNA Helicase Cancer Targets, oncogenes, pathfinder molecules, Pathfinder Molecules Show Potential to Unlock New Family of Cancer Drug Targets, pre-mRNA splicing, protein translation, RNA binding, RNA helicase family, RNA processing, RNA-competitive inhibitors, small molecule inhibitors, spliceosome, structural biology, structure-guided medicinal chemistry, target engagement, The Institute of Cancer Research London, therapeutic cancer targets, underexploited drug targets, X-ray crystallography
(IN BRIEF) Researchers at the University of Copenhagen and their collaborators found that adults with type 2 diabetes who do not consistently take their prescribed glucose-lowering medication have a higher rate of cardiovascular disease. The study followed 79,510 adults newly … Read the full press release
Posted in Denmark, Education, Healthcare, Pharma & Biotech, Science
Tagged Andreas Bartholdy, blood sugar control, blood vessels, cardiovascular disease, cardiovascular risk before age 55, CBMR, chronic disease management, clinical decision making, comorbidities, Danish national health registries, Danish Registry Study Highlights Importance of Staying on Diabetes Medication, Denmark, diabetes medication, diabetes treatment support, glucose-lowering therapy, heart attacks, heart health, Ischemic heart disease, Jordi Merino, Lise B Nielsen, long-term adherence, lower income, Majken K Jensen, major cardiovascular events, Marta Guasch-Ferré, medication adherence, nationwide cohort study, non-insulin medication, Novo Nordisk Foundation, Novo Nordisk Foundation Center for Basic Metabolic Research, observational study, patients living alone, personalised patient support, pharmacy records, prescription records, public health, Simon Rasmussen, socioeconomic factors, strokes, The Lancet Regional Health Europe, Tri-Long Nguyen, type 2 diabetes, Type 2 Diabetes Patients With Low Medication Adherence Face Higher Heart Disease Risk, University of Copenhagen, younger adults, Younger Type 2 Diabetes Patients Face Higher Cardiovascular Risk When Treatment Adherence Drops
(IN BRIEF) The MRC-University of Glasgow Centre for Virus Research is playing a leading role in DETECTIVE, a new European doctoral training programme backed by €4.4 million in EU funding through the Horizon Europe Marie Skłodowska-Curie Actions Doctoral Network programme. … Read the full press release
Posted in Artificial Intelligence (AI), Business, Denmark, Education, European Union, Financial, Finland, Healthcare, Netherlands, Pharma & Biotech, Science, Spain, Technology, United Kingdom
Tagged 14 doctoral researchers, academic partners, AI-based analytics, Amsterdam University Medical Centre, artificial intelligence, blood-donor surveillance, clinical data, culture models, CVR, CVR Takes Leading Role in European Effort to Strengthen Viral Surveillance and Pandemic Preparedness, Data driven Excellence in Training of Epidemiological Clinical Technological and Innovative Virus Experts, data science, Denmark, DETECTIVE, diagnostics, doctoral researchers, Doctoral Training, Dr Ana Filipe, Dutch National Institute for Public Health and the Environment, emerging viral threats, epidemic intelligence, European Commission, evidence-based decision making, Finland, healthcare delivery, healthcare partners, Horizon Europe, Horizon Europe Funding Supports New Doctoral Training Programme for Epidemic Intelligence, human viral diseases, human-animal interface, industry partners, infectious diseases, Marie Skłodowska-Curie Actions, MRC-University of Glasgow Centre for Virus Research, MSCA Doctoral Network, multi-omics, Netherlands, next-generation sequencing, Nordsjællands Hospital, organoid models, outbreak detection, outbreak response, Pandemic Preparedness, Professor Antonia Ho, public health, re-emerging viral infections, RIVM, Scotland, seven research institutions, severe respiratory infections, Spain, Tampere University, United Kingdom, University College London, University of Copenhagen, University of Glasgow, University of Glasgow Researchers to Lead Projects in European Virus Detection Network, University of Turku, UofG, Vall d’Hebron University Hospital Barcelona, viral genomics, viral surveillance, virology, wastewater surveillance, €4.4 million EU funding
(IN BRIEF) Scientists at The Institute of Cancer Research, London have identified features in some aggressive cancer cells that may make them vulnerable to ROCK inhibitors, a group of drugs already used to treat glaucoma. The research found relevant markers … Read the full press release
Posted in Business, Education, Healthcare, Non Profit, Pharma & Biotech, Science, Technology, United Kingdom
Tagged acute myeloid leukaemia, aggressive cancer cells, AML, Barts Cancer Institute, Barts Charity, biomarker discovery, breast cancer, Breast Cancer Now, Breast Cancer Now Toby Robins Research Centre, cancer cell biology, Cancer Cell Shape and Gene Patterns May Help Identify Patients Suitable for Glaucoma Drug Trials, cancer research, Cancer Research UK, cancer spread, cell scaffolding, clinical trials, Dr Simon Vincent, drug repurposing, drug sensitivity database, E-Cadherin, epithelial solid tumours, glaucoma drugs, ICR, ICR Study Opens Path Toward Testing ROCK Inhibitors in Personalised Cancer Treatment, invasive border, iScience, Jaume Barcelo, laboratory validation, melanoma, metastasis, metastatic cancer, molecular fingerprint, mouse studies, NFKB, NHS glaucoma treatment, non-epithelial solid tumours, patient biopsies, personalised cancer treatment, Professor Victoria Sanz Moreno, Queen Mary University of London, Rho kinase, ROCK inhibitors, rounded cancer cells, The Institute of Cancer Research London, treatment resistance, tumour growth, tumour inflammation, tumour invasion, tumour samples, UK Research and Innovation, UKRI, Worldwide Cancer Research
(IN BRIEF) Basilea Pharmaceutica Ltd has received an additional USD 5.4 million from BARDA to continue development of its novel oral antibiotic ceftibuten-ledaborbactam etzadroxil. The antibiotic is being developed for complicated urinary tract infections, including pyelonephritis, particularly infections caused by … Read the full press release
Posted in Business, Financial, Government, Healthcare, Investment, Pharma & Biotech, Science, Switzerland, Technology
Tagged Additional BARDA Support Brings Basilea Funding for Ceftibuten-Ledaborbactam to USD 30.8 Million, Administration for Strategic Preparedness and Response, Allschwil, anti-infectives, antimicrobial resistance, ASPR, BARDA, BARDA Awards Further Funding to Basilea for Ceftibuten-Ledaborbactam Development, Basilea, Basilea Advances Oral Antibiotic Candidate for Complicated Urinary Tract Infections, Basilea Pharmaceutica, Basilea Pharmaceutica Ltd, beta lactam beta lactamase inhibitor, Biomedical Advanced Research and Development Authority, BL/BLI, boronic acid beta-lactamase inhibitor, BSLN, carbapenemases, ceftibuten, ceftibuten ledaborbactam etzadroxil, ceftibuten-ledaborbactam, cephalosporinases, complicated urinary tract infections, Cresemba®, cUTI, David Veitch, Enterobacterales, ESBL, extended spectrum beta-lactamases, Fast Track Designation, fungal infections, Gram-negative bacteria, investigational drug, KPC, ledaborbactam, ledaborbactam etzadroxil, multidrug resistant bacteria, non-dilutive funding, novel oral antibiotic, oral cephalosporin, OXA-48, pyelonephritis, QIDP designation, Qualified Infectious Disease Product, Severe Bacterial Infections, SIX Swiss Exchange, Switzerland, U.S Department of Health and Human Services, U.S. FDA, USD 172 million contract potential, USD 30.8 million total funding, USD 5.4 million funding, Zevtera®
(IN BRIEF) Adyen will provide payment technology services for LillyDirect, supporting patients who access Lilly’s FDA-approved medicines and free home delivery through the platform. LillyDirect will use Adyen’s platform to offer flexible payment options, including credit and debit cards, Apple … Read the full press release
Posted in Artificial Intelligence (AI), Business, Financial, Healthcare, Internet & Online, Investment, Netherlands, Pharma & Biotech, Security & Safety, Technology
Tagged Adyen, Adyen Brings Intelligent Payment Routing to LillyDirect Transactions, Adyen Supports Direct-to-Consumer Healthcare Payments for LillyDirect, Adyen Technology to Support Secure Checkout and Payment Flexibility for LillyDirect, AI-powered payments, analytics, Apple Pay, checkout process, consumer convenience, credit cards, debit cards, digital healthcare platforms, digital wallets, direct-to-consumer healthcare, end-to-end payments, FDA-approved medicines, financial technology, fintech, flexible payment options, fraud prevention, free home delivery, FSA cards, Google Pay, Head of Health and Wellness at Adyen, healthcare payments, HSA cards, Intelligent Payment Routing, Lilly, LillyDirect, Matthew Fanelli, online payments, patient payments, payment optimisation, payment performance, payment reconciliation, payment technology, platform scalability, prescribed patients, secure payment experience, U.S. debit network, U.S. healthcare industry
(IN BRIEF) Fresenius Kabi, an operating company of Fresenius, has announced that the U.S. FDA has approved a rituximab biosimilar developed by Dr. Reddy’s Laboratories for the U.S. market. Under an exclusive commercialisation agreement, Fresenius Kabi holds the U.S. commercialisation … Read the full press release
Posted in Business, Germany, Government, Healthcare, Pharma & Biotech, Science
Tagged #FutureFresenius, affordable biologic therapies, analytical data, autoimmune diseases, B cells, B lymphocytes, B-cell malignancies, Bad Homburg v. d. Höhe, biologic medicines, biopharma, biopharmaceuticals, Biosimilar, biosimilars portfolio, CD20 antigen, chronic lymphocytic leukemia, clinical data, clinical nutrition, Dr. Eduard Fresenius, Dr. Reddy’s, Dr. Reddy’s Laboratories, Dr. Sang-Jin Pak, Else Kröner, Else Kröner Fresenius Foundation, exclusive commercialisation agreement, FDA, FDA approval, FDA Approves Dr. Reddy’s Rituximab Biosimilar for U.S. Commercialisation by Fresenius Kabi, Fresenius, Fresenius Helios, Fresenius Kabi, Fresenius Kabi Announces FDA Approval of Rituximab Biosimilar for U.S. Market, Fresenius Kabi Strengthens U.S. Biosimilars Portfolio With Rituximab Approval, Fresenius Medical Care, Fresenius SE & Co KGaA, Genentech, Germany, GPA, granulomatosis with polyangiitis, hematologic malignancies, immunology, intravenous generic drugs, medical technology, microscopic polyangiitis, monoclonal antibody, MPA, Nicole Meier, non-clinical data, Non-Hodgkin lymphoma, oncology, patient access, pharmacokinetic studies, rheumatoid arthritis, Rituxan, rituximab, rituximab biosimilar, totality of the evidence, U.S. Food and Drug Administration, U.S. market
(IN BRIEF) Kuehne+Nagel has expanded its Cool Corridor network for temperature-sensitive healthcare logistics by adding four new airfreight routes: Frankfurt–Atlanta, Chicago–Narita, Brussels–São Paulo, and Chicago–São Paulo. The expansion brings the network to 12 airfreight lanes connecting major pharmaceutical and healthcare … Read the full press release
Posted in Aviation & Aerospace, Belgium, Business, Environment, Germany, Healthcare, International Trade, Pharma & Biotech, Switzerland, Technology, Transportation & Logistics
Tagged active containers, airfreight, airlines, Atlanta, biologics, Boeing 747-8 Freighter, Brussels, Chicago, cold chain efficiency, cold chain logistics, Cool Corridor, Cool Corridor Expansion Supports More Efficient and Sustainable Pharmaceutical Logistics, Dorothee Becher, end-to-end transportation, Frankfurt, GDP-compliant handling, Global Air Logistics Healthcare, good distribution practice, ground handlers, Healthcare Logistics, healthcare supply chains, Inspire, Kuehne+Nagel, Kuehne+Nagel Strengthens Global Healthcare Logistics With Expanded Cool Corridor Network, logistics costs, Narita, New Cool Corridor Routes Connect Major Pharmaceutical Hubs Across Four Regions, passive packaging, peptides, pharmaceutical hubs, pharmaceutical logistics, product integrity, São Paulo, Schindellegi, Switzerland, temperature excursions, temperature-sensitive pharmaceuticals, temperature-sensitive products, Time Out of Range, ToR, transport emissions, vaccines
(IN BRIEF) Researchers at the University of Liverpool and the University of Oxford have developed an experimental targeted therapy designed to kill antibiotic-resistant Neisseria gonorrhoeae, the bacterium that causes gonorrhoea. The approach uses an antibody-drug conjugate made up of an … Read the full press release
Posted in Education, Healthcare, Pharma & Biotech, Science, Technology, United Kingdom
Tagged ADC, AMR, antibiotic-resistant gonorrhoea, antibody-drug conjugate, antimicrobial payload, antimicrobial peptide, antimicrobial resistance, bacterial biology, bacterial enzyme, bacterial surface activation, Candida auris, cellular pathology, Christoph Tang, doi 10.1073/pnas.2534217123, drug-resistant infections, first-line antibiotics, Gonorrhoea, Hayley Lavender, human cell toxicity, IgA protease, immune evasion, infectious disease research, laboratory testing, microbial pathogenesis, molecular linker, multidrug resistant bacteria, N. gonorrhoeae, Neisseria gonorrhoeae, Novel Antibody-Drug Conjugate Shows Promise Against Multidrug-Resistant Neisseria Gonorrhoeae, PNAS, precision antimicrobial therapy, preclinical research, Research Team Develops Precision Antimicrobial Method for Resistant Gonorrhoea, sexually transmitted infection, STI, Targeted Antimicrobial Platform Uses Bacterial Enzyme to Attack Resistant Gonorrhoea, targeted therapy, University of Liverpool, University of Oxford
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions. Here you can learn more about EuropaWire’s mission, achievements, services, etc.
HOW TO GET STARTED?